Clinical-economic impact of the change of protocol for use of basiliximab in liver transplant.
CONCLUSIONS: In our population, the protocol change making universal the first dose of basiliximab has not shown the expected benefits, but an increase in costs, so the suitability of the new protocol in consensus with the medical team must be reconsidered. The evidence regarding the use of basiliximab in orthohepatic transplant remains limited and although its benefit seems clear in patients with risk factors, especially renal failure, recommendations about its use universally remains controversial.
PMID: 30624168 [PubMed - in process]
Source: Farmacia Hospitalaria - Category: Drugs & Pharmacology Authors: Plasencia-GarcÃa I, Tévar-Alfonso E, González-RodrÃguez A, Moreno-GarcÃa A, Merino-Alonso J, Aguirre-Jaime A Tags: Farm Hosp Source Type: research
More News: Drugs & Pharmacology | Liver | Liver Transplant | Renal Failure | Study | Transplant Surgery | Transplants | Urology & Nephrology